Safety Alerts & Recalls
What does this mean?
If you are taking Raptiva, you should contact your physician right away to discuss how to transition to an alternative treatment for your psoriasis.
Withdrawal of Raptiva (efalizumab) From the U.S. Market
Genentech announced that it has begun a phased withdrawal of Raptiva (efalizumab) from the U.S. market. The product is being withdrawn because patients are at risk for developing a rare, serious infection that may affect the brain called progressive multifocal leukoencephalopathy (PML). By June 8, 2009, Raptiva will no longer be available in the United States.
For more information, please visit: more information here